Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

Immunogenomic Analysis of Exceptional Responder to ALT-803 (IL-15 Analogue) in BCG Unresponsive Nonmuscle Invasive Bladder Cancer: A Case Series and Review of the Literature.

Huang J, Shiao SL, Furuya H, Rosser CJ.

J Immunother. 2019 Nov/Dec;42(9):354-358. doi: 10.1097/CJI.0000000000000269.

PMID:
31107371
2.

Mycoplasma genitalium Infection and Chronic Inflammation in Human Prostate Cancer: Detection Using Prostatectomy and Needle Biopsy Specimens.

Miyake M, Ohnishi K, Hori S, Nakano A, Nakano R, Yano H, Ohnishi S, Owari T, Morizawa Y, Itami Y, Nakai Y, Inoue T, Anai S, Torimoto K, Tanaka N, Fujii T, Furuya H, Rosser CJ, Fujimoto K.

Cells. 2019 Mar 2;8(3). pii: E212. doi: 10.3390/cells8030212.

3.

Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral Growth.

Miyake M, Furuya H, Onishi S, Hokutan K, Anai S, Chan O, Shi S, Fujimoto K, Goodison S, Cai W, Rosser CJ.

Theranostics. 2019 Jan 25;9(3):853-867. doi: 10.7150/thno.29553. eCollection 2019.

4.

Nutritional implications for quality of life in bladder cancer survivors.

Rosser CJ.

Transl Androl Urol. 2018 Dec;7(Suppl 6):S688-S691. doi: 10.21037/tau.2018.12.02. No abstract available.

5.

Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model.

Furuya H, Chan OTM, Pagano I, Zhu C, Kim N, Peres R, Hokutan K, Alter S, Rhode P, Rosser CJ.

J Transl Med. 2019 Jan 17;17(1):29. doi: 10.1186/s12967-019-1778-6.

6.

Urinary Cytokine Profile to Predict Response to Intravesical BCG with or without HS-410 Therapy in Patients with Non-muscle-invasive Bladder Cancer.

Salmasi A, Elashoff DA, Guo R, Upfill-Brown A, Rosser CJ, Rose JM, Giffin LC, Gonzalez LE, Chamie K.

Cancer Epidemiol Biomarkers Prev. 2019 Jun;28(6):1036-1044. doi: 10.1158/1055-9965.EPI-18-0893. Epub 2018 Dec 28.

PMID:
30593457
7.

Diagnostic biomarkers in non-muscle invasive bladder cancer.

Faiena I, Rosser CJ, Chamie K, Furuya H.

World J Urol. 2019 Oct;37(10):2009-2016. doi: 10.1007/s00345-018-2567-1. Epub 2018 Nov 22.

PMID:
30467596
8.

Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer.

Masuda N, Ogawa O, Park M, Liu AY, Goodison S, Dai Y, Kozai L, Furuya H, Lotan Y, Rosser CJ, Kobayashi T.

Oncotarget. 2018 Jan 3;9(6):7101-7111. doi: 10.18632/oncotarget.23872. eCollection 2018 Jan 23.

9.

Erratum to: Urinary Protein Markers for the Detection and Prognostication of Urothelial Carcinoma.

Szarvas T, Nyirády P, Ogawa O, Furuya H, Rosser CJ, Kobayashi T.

Methods Mol Biol. 2018;1655:E1. doi: 10.1007/978-1-4939-7234-0_25. No abstract available.

PMID:
29442339
10.

Association of MMP-2, RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients.

Chan OTM, Furuya H, Pagano I, Shimizu Y, Hokutan K, Dyrskjøt L, Jensen JB, Malmstrom PU, Segersten U, Janku F, Rosser CJ.

Oncotarget. 2017 Sep 6;8(59):99707-99721. doi: 10.18632/oncotarget.20686. eCollection 2017 Nov 21.

11.

Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in an HER2 transgenic model.

Shimizu Y, Furuya H, Tamashiro PM, Iino K, Chan OTM, Goodison S, Pagano I, Hokutan K, Peres R, Loo LWM, Hernandez B, Naing A, Chong CDK, Rosser CJ, Kawamori T.

Carcinogenesis. 2018 Jan 12;39(1):47-55. doi: 10.1093/carcin/bgx097.

12.

Urinary Protein Markers for the Detection and Prognostication of Urothelial Carcinoma.

Szarvas T, Nyirády P, Ogawa O, Furuya H, Rosser CJ, Kobayashi T.

Methods Mol Biol. 2018;1655:251-273. doi: 10.1007/978-1-4939-7234-0_19. Review. Erratum in: Methods Mol Biol. 2018;1655:E1.

PMID:
28889391
13.

Intravesical ALT-803 for BCG-unresponsive Bladder Cancer - A Case Report.

Huang J, Schisler J, Wong HC, Rosser CJ, Sterbis J.

Urol Case Rep. 2017 Jun 8;14:15-17. doi: 10.1016/j.eucr.2017.04.015. eCollection 2017 Sep.

14.

Reply to 'It May be Time to Abandon Urine Tests for Bladder Cancer'.

Furuya H, Rosser CJ, Inman BA, Fantony JJ.

J Natl Compr Canc Netw. 2017 May;15(5):lxx-lxxii. No abstract available.

PMID:
28476745
15.

On the brink of extinction: the future of translational physician-scientists in the United States.

Furuya H, Brenner D, Rosser CJ.

J Transl Med. 2017 May 1;15(1):88. doi: 10.1186/s12967-017-1188-6.

16.

Corrigendum to "CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer" [Neoplasia 18 (2016) 636-646].

Miyake M, Hori S, Morizawa Y, Tatsumi Y, Nakai Y, Anai S, Torimoto K, Aoki K, Tanaka N, Shimada K, Konishi N, Toritsuka M, Kishimoto T, Rosser CJ, Fujimoto K.

Neoplasia. 2017 Mar;19(3):250-251. doi: 10.1016/j.neo.2016.12.012. No abstract available.

17.

A microRNA biomarker panel for the non-invasive detection of bladder cancer.

Urquidi V, Netherton M, Gomes-Giacoia E, Serie DJ, Eckel-Passow J, Rosser CJ, Goodison S.

Oncotarget. 2016 Dec 27;7(52):86290-86299. doi: 10.18632/oncotarget.13382.

18.

Urinary mRNA biomarker panel for the detection of urothelial carcinoma.

Urquidi V, Netherton M, Gomes-Giacoia E, Serie D, Eckel-Passow J, Rosser CJ, Goodison S.

Oncotarget. 2016 Jun 21;7(25):38731-38740. doi: 10.18632/oncotarget.9587.

19.

A multiplex urinary immunoassay for bladder cancer detection: analysis of a Japanese cohort.

Goodison S, Ogawa O, Matsui Y, Kobayashi T, Miyake M, Ohnishi S, Fujimoto K, Dai Y, Shimizu Y, Tsukikawa K, Furuya H, Rosser CJ.

J Transl Med. 2016 Oct 7;14(1):287.

20.

CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer.

Miyake M, Hori S, Morizawa Y, Tatsumi Y, Nakai Y, Anai S, Torimoto K, Aoki K, Tanaka N, Shimada K, Konishi N, Toritsuka M, Kishimoto T, Rosser CJ, Fujimoto K.

Neoplasia. 2016 Oct;18(10):636-646. doi: 10.1016/j.neo.2016.08.002. Epub 2016 Sep 28. Erratum in: Neoplasia. 2017 Mar;19(3):250-251.

21.

A Nomogram Derived by Combination of Demographic and Biomarker Data Improves the Noninvasive Evaluation of Patients at Risk for Bladder Cancer.

Huang S, Kou L, Furuya H, Yu C, Goodison S, Kattan MW, Garmire L, Rosser CJ.

Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1361-6. doi: 10.1158/1055-9965.EPI-16-0260. Epub 2016 Jul 6.

22.

Angiogenin contributes to bladder cancer tumorigenesis by DNMT3b-mediated MMP2 activation.

Peres R, Furuya H, Pagano I, Shimizu Y, Hokutan K, Rosser CJ.

Oncotarget. 2016 Jul 12;7(28):43109-43123. doi: 10.18632/oncotarget.10097.

23.

Bladder cancer cells secrete while normal bladder cells express but do not secrete AGR2.

Ho ME, Quek SI, True LD, Seiler R, Fleischmann A, Bagryanova L, Kim SR, Chia D, Goodglick L, Shimizu Y, Rosser CJ, Gao Y, Liu AY.

Oncotarget. 2016 Mar 29;7(13):15747-56. doi: 10.18632/oncotarget.7400.

24.

The Influence of Race on Overall Survival in Patients with Newly Diagnosed Bladder Cancer.

DeDeugd C, Miyake M, Palacios DA, Rosser CJ.

J Racial Ethn Health Disparities. 2015 Mar;2(1):124-31. doi: 10.1007/s40615-014-0055-x. Epub 2014 Sep 11.

PMID:
26863249
25.

A multiplex immunoassay for the non-invasive detection of bladder cancer.

Shimizu Y, Furuya H, Bryant Greenwood P, Chan O, Dai Y, Thornquist MD, Goodison S, Rosser CJ.

J Transl Med. 2016 Jan 30;14:31. doi: 10.1186/s12967-016-0783-2.

26.

A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer.

Paladino D, Yue P, Furuya H, Acoba J, Rosser CJ, Turkson J.

Oncotarget. 2016 Feb 9;7(6):7253-67. doi: 10.18632/oncotarget.6635.

27.

CXCL1 is elevated in the urine of bladder cancer patients.

Burnier A, Shimizu Y, Dai Y, Nakashima M, Matsui Y, Ogawa O, Rosser CJ, Furuya H.

Springerplus. 2015 Oct 15;4:610. doi: 10.1186/s40064-015-1393-9. eCollection 2015.

28.

Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature.

Zhang G, Gomes-Giacoia E, Dai Y, Lawton A, Miyake M, Furuya H, Goodison S, Rosser CJ.

Diagn Pathol. 2014 Nov 12;9:200. doi: 10.1186/s13000-014-0200-1.

29.

External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort.

Chen LM, Chang M, Dai Y, Chai KX, Dyrskjøt L, Sanchez-Carbayo M, Szarvas T, Zwarthoff EC, Lokeshwar V, Jeronimo C, Parker AS, Ross S, Borre M, Orntoft TF, Jaeger T, Beukers W, Lopez LE, Henrique R, Young PR, Urquidi V, Goodison S, Rosser CJ.

Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1804-12. doi: 10.1158/1055-9965.EPI-14-0029. Epub 2014 Jun 11.

30.

Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion.

Gomes-Giacoia E, Miyake M, Goodison S, Sriharan A, Zhang G, You L, Egan JO, Rhode PR, Parker AS, Chai KX, Wong HC, Rosser CJ.

PLoS One. 2014 Jun 4;9(6):e96705. doi: 10.1371/journal.pone.0096705. eCollection 2014.

31.

Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors.

Zhang G, Miyake M, Lawton A, Goodison S, Rosser CJ.

BMC Cancer. 2014 May 3;14:310. doi: 10.1186/1471-2407-14-310.

32.

Urinary protein biomarker panel for the detection of recurrent bladder cancer.

Rosser CJ, Chang M, Dai Y, Ross S, Mengual L, Alcaraz A, Goodison S.

Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1340-5. doi: 10.1158/1055-9965.EPI-14-0035. Epub 2014 Apr 8.

33.

Simultaneous multi-analyte urinary protein assay for bladder cancer detection.

Rosser CJ, Dai Y, Miyake M, Zhang G, Goodison S.

BMC Biotechnol. 2014 Apr 1;14:24. doi: 10.1186/1472-6750-14-24.

34.

Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1/2 pathway.

Miyake M, Goodison S, Lawton A, Gomes-Giacoia E, Rosser CJ.

Oncogene. 2015 Feb 12;34(7):890-901. doi: 10.1038/onc.2014.2. Epub 2014 Feb 24.

35.

MULTIPLEX URINARY TESTS FOR BLADDER CANCER DIAGNOSIS.

Urquidi V, Rosser CJ, Goodison S.

Eur Med J Urol. 2013;1:70-73.

36.

Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer.

Miyake M, Lawton A, Dai Y, Chang M, Mengual L, Alcaraz A, Goodison S, Rosser CJ.

BMC Cancer. 2014 Feb 13;14:86. doi: 10.1186/1471-2407-14-86.

37.

PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation.

Giacoia EG, Miyake M, Lawton A, Goodison S, Rosser CJ.

Mol Cancer Res. 2014 Mar;12(3):322-34. doi: 10.1158/1541-7786.MCR-13-0543. Epub 2014 Jan 24.

38.

The Postoperative Morbidity Index: a quantitative weighing of postoperative complications applied to urological procedures.

Beilan J, Strakosha R, Palacios DA, Rosser CJ.

BMC Urol. 2014 Jan 3;14:1. doi: 10.1186/1471-2490-14-1.

39.

Differential expression of SDF-1 isoforms in bladder cancer.

Gosalbez M, Hupe MC, Lokeshwar SD, Yates TJ, Shields J, Veerapen MK, Merseburger AS, Rosser CJ, Soloway MS, Lokeshwar VB.

J Urol. 2014 Jun;191(6):1899-1905. doi: 10.1016/j.juro.2013.11.053. Epub 2013 Nov 26.

40.

Chemokine (C-X-C motif) ligand 1 (CXCL1) protein expression is increased in high-grade prostate cancer.

Miyake M, Lawton A, Goodison S, Urquidi V, Rosser CJ.

Pathol Res Pract. 2014 Feb;210(2):74-8. doi: 10.1016/j.prp.2013.08.013. Epub 2013 Oct 28.

PMID:
24252309
41.

Pilot study comparing the two hemostatic agents in patients undergoing partial nephrectomy.

Palacios DA, McDonald M, Miyake M, Rosser CJ.

BMC Res Notes. 2013 Oct 3;6:399. doi: 10.1186/1756-0500-6-399.

42.

Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model.

Gomes-Giacoia E, Miyake M, Goodison S, Rosser CJ.

Mol Cancer Ther. 2013 Dec;12(12):2697-708. doi: 10.1158/1535-7163.MCT-13-0500. Epub 2013 Sep 26.

43.

Urinary biomarkers of bladder cancer: an update and future perspectives.

Rosser CJ, Urquidi V, Goodison S.

Biomark Med. 2013 Oct;7(5):779-90. doi: 10.2217/bmm.13.73. Review.

PMID:
24044570
44.

Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection.

Miyake M, Ross S, Lawton A, Chang M, Dai Y, Mengual L, Alcaraz A, Giacoia EG, Goodison S, Rosser CJ.

BMC Urol. 2013 Sep 5;13:42. doi: 10.1186/1471-2490-13-42.

45.

Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions.

Miyake M, Goodison S, Lawton A, Zhang G, Gomes-Giacoia E, Rosser CJ.

J Hematol Oncol. 2013 Sep 3;6:65. doi: 10.1186/1756-8722-6-65.

46.

Attitudes and knowledge of primary care physicians regarding prostate cancer screening.

Johnson K, Chang M, Sun Y, Miyake M, Rosser CJ.

J Cancer Educ. 2013 Dec;28(4):679-83. doi: 10.1007/s13187-013-0533-6.

PMID:
23963724
47.

Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers.

Miyake M, Lawton A, Goodison S, Urquidi V, Gomes-Giacoia E, Zhang G, Ross S, Kim J, Rosser CJ.

BMC Cancer. 2013 Jul 1;13:322. doi: 10.1186/1471-2407-13-322.

48.

Multiplex protein signature for the detection of bladder cancer in voided urine samples.

Rosser CJ, Ross S, Chang M, Dai Y, Mengual L, Zhang G, Kim J, Urquidi V, Alcaraz A, Goodison S.

J Urol. 2013 Dec;190(6):2257-62. doi: 10.1016/j.juro.2013.06.011. Epub 2013 Jun 11.

49.

Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1/2 and EGF pathways.

Miyake M, Goodison S, Urquidi V, Gomes Giacoia E, Rosser CJ.

Lab Invest. 2013 Jul;93(7):768-78. doi: 10.1038/labinvest.2013.71. Epub 2013 Jun 3.

50.

Long-term exposure to cigarette smoke extract induces hypomethylation at the RUNX3 and IGF2-H19 loci in immortalized human urothelial cells.

Chen LM, Nergard JC, Ni L, Rosser CJ, Chai KX.

PLoS One. 2013 May 28;8(5):e65513. doi: 10.1371/journal.pone.0065513. Print 2013.

Supplemental Content

Loading ...
Support Center